The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations

Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain (London, England : 1878) England : 1878), 2004-12, Vol.127 (12), p.2657-2671
Hauptverfasser: Ozawa, Tetsutaro, Paviour, Dominic, Quinn, Niall P., Josephs, Keith A., Sangha, Hardev, Kilford, Linda, Healy, Daniel G., Wood, Nick W., Lees, Andrew J., Holton, Janice L., Revesz, Tamas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2671
container_issue 12
container_start_page 2657
container_title Brain (London, England : 1878)
container_volume 127
creator Ozawa, Tetsutaro
Paviour, Dominic
Quinn, Niall P.
Josephs, Keith A.
Sangha, Hardev
Kilford, Linda
Healy, Daniel G.
Wood, Nick W.
Lees, Andrew J.
Holton, Janice L.
Revesz, Tamas
description Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis of 100 MSA cases with well-characterized clinical phenotypes. In 24 areas, chosen from both the striatonigral (StrN) and olivopontocerebellar (OPC) regions, the severity of neuronal cell loss and gliosis as well as the frequency of glial (oligodendroglial) cytoplasmic inclusions (GCIs) and neuronal cytoplasmic inclusions (NCIs) were determined. Clinical information was abstracted from the patients' medical records, and the severity of bradykinesia in the first year of disease onset and in the final stages of disease was graded retrospectively. The degree of levodopa responsiveness and the presence or absence of cerebellar ataxia and autonomic symptoms were also recorded. We report that 34% of the cases were SND- and 17% were OPCA-predominant, while the remainder (49%) had equivalent SND and OPCA pathology. We found a significant correlation between the frequency of GCIs and the severity of neuronal cell loss, and between these pathological changes and disease duration. Our data also suggest that GCIs may have more influence on the OPC than on the StrN pathology. Moreover, we raise the possibility that a rapid process of neuronal cell loss, which is independent of the accumulation of GCIs, occurs in the StrN region in MSA. There was no difference in the frequency of NCIs in the putamen, pontine nucleus and inferior olivary nucleus between the SND and OPCA subtypes of MSA, confirming that this pathological abnormality is not associated with a particular subtype of the disease. In the current large post-mortem series, 10% of the cases had associated Lewy body pathology, suggesting that this is not a primary process in MSA. As might be expected, there was a significant difference in the severity of bradykinesia and the presence of cerebellar signs between the pathological phenotypes: the SND phenotype demonstrates the most severe bradykinesia and the OPCA phenotype the more frequent occurrence of cerebellar signs, confirming that the clinical phenotype is dependent on the distribution of pathology within the basal ganglia and cerebellum. Putaminal involvement correlated with a poor levodopa response in MSA. Our finding that relatively mild involvement of the substant
doi_str_mv 10.1093/brain/awh303
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67097096</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>754521171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-91e18e92df76b60b5fbea9ac869209ecc390e343c94763151258e3f6047a2f953</originalsourceid><addsrcrecordid>eNqF0UGL1DAYBuAgijuu3jxLEfRk3aRp0mZvOqirDAiyguwlpJmvO1nTpCbp6PwW_6ypU1z0IgQCycMbvrwIPSb4JcGCnnVBGXemvu8opnfQitQclxVh_C5aYYx52QqGT9CDGG8wJjWt-H10QhjDgld0hX5e7qCII-gUpqHwfTGqtPPWXxutbGHc3ts9DODSfJdmm4JRyTtzHTJQblt4a_Z-9C55DQE6sFaFIh5igiHmhGKYbDKjheWsUCn4cXc4L7Q1zmj_14vahwBWJeNdfIju9cpGeLTsp-jz2zeX64ty8_Hd-_WrTalrRlMpCJAWRLXtG95x3LG-AyWUbrmosACtqcBAa6pF3XBKGKlYC7TnuG5U1QtGT9HzY-4Y_LcJYpKDiXqew4GfouQNFnnx_0IiuBAtnhOf_gNv_BRcHiIbNpcg6oxeHJEOPsYAvRyDGVQ4SILlXK38Xa08Vpv5kyVz6gbY3uKlywyeLUDF_JV9UE6beOs4pQ3hTXbl0Zlcx48_9yp8zZPShsmLL1eyEa83n9ZXHySlvwBWLcFW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195432694</pqid></control><display><type>article</type><title>The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations</title><source>Oxford University Press Journals</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Ozawa, Tetsutaro ; Paviour, Dominic ; Quinn, Niall P. ; Josephs, Keith A. ; Sangha, Hardev ; Kilford, Linda ; Healy, Daniel G. ; Wood, Nick W. ; Lees, Andrew J. ; Holton, Janice L. ; Revesz, Tamas</creator><creatorcontrib>Ozawa, Tetsutaro ; Paviour, Dominic ; Quinn, Niall P. ; Josephs, Keith A. ; Sangha, Hardev ; Kilford, Linda ; Healy, Daniel G. ; Wood, Nick W. ; Lees, Andrew J. ; Holton, Janice L. ; Revesz, Tamas</creatorcontrib><description>Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis of 100 MSA cases with well-characterized clinical phenotypes. In 24 areas, chosen from both the striatonigral (StrN) and olivopontocerebellar (OPC) regions, the severity of neuronal cell loss and gliosis as well as the frequency of glial (oligodendroglial) cytoplasmic inclusions (GCIs) and neuronal cytoplasmic inclusions (NCIs) were determined. Clinical information was abstracted from the patients' medical records, and the severity of bradykinesia in the first year of disease onset and in the final stages of disease was graded retrospectively. The degree of levodopa responsiveness and the presence or absence of cerebellar ataxia and autonomic symptoms were also recorded. We report that 34% of the cases were SND- and 17% were OPCA-predominant, while the remainder (49%) had equivalent SND and OPCA pathology. We found a significant correlation between the frequency of GCIs and the severity of neuronal cell loss, and between these pathological changes and disease duration. Our data also suggest that GCIs may have more influence on the OPC than on the StrN pathology. Moreover, we raise the possibility that a rapid process of neuronal cell loss, which is independent of the accumulation of GCIs, occurs in the StrN region in MSA. There was no difference in the frequency of NCIs in the putamen, pontine nucleus and inferior olivary nucleus between the SND and OPCA subtypes of MSA, confirming that this pathological abnormality is not associated with a particular subtype of the disease. In the current large post-mortem series, 10% of the cases had associated Lewy body pathology, suggesting that this is not a primary process in MSA. As might be expected, there was a significant difference in the severity of bradykinesia and the presence of cerebellar signs between the pathological phenotypes: the SND phenotype demonstrates the most severe bradykinesia and the OPCA phenotype the more frequent occurrence of cerebellar signs, confirming that the clinical phenotype is dependent on the distribution of pathology within the basal ganglia and cerebellum. Putaminal involvement correlated with a poor levodopa response in MSA. Our finding that relatively mild involvement of the substantia nigra is associated clinically with manifest parkinsonism, while more advanced cerebellar pathology is required for ataxia, may explain why the parkinsonian presentation is predominant over ataxia in MSA.</description><identifier>ISSN: 0006-8950</identifier><identifier>ISSN: 1460-2156</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/awh303</identifier><identifier>PMID: 15509623</identifier><identifier>CODEN: BRAIAK</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Age Distribution ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cell Death ; clinicopathological correlations ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; GCI = glial cytoplasmic inclusion ; GFAP = glial fibrillary acidic protein ; glial cytoplasmic inclusion ; H&amp;E = haematoxylin and eosin ; Humans ; IPD = idiopathic Parkinson's disease ; Lewy Bodies - pathology ; LFB/CV = luxol fast blue/cresyl violet ; Male ; Medical sciences ; Middle Aged ; MSA = multiple system atrophy ; MSA-C = multiple system atrophy cerebellar type ; MSA-P = multiple system atrophy parkinsonism ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; multiple system atrophy ; Multiple System Atrophy - pathology ; NCI = neuronal cytoplasmic inclusion ; NCLPS = neuronal cell loss predominance score ; Neurology ; Neurons - pathology ; Olivopontocerebellar Atrophies - pathology ; olivopontocerebellar atrophy ; OPC = olivopontocerebellar ; OPCA = olivopontocerebellar atrophy ; Phenotype ; QSBB = Queen Square Brain Bank ; SbN = substantia nigra ; Severity of Illness Index ; Sex Distribution ; SND = striatonigral degeneration ; striatonigral degeneration ; Striatonigral Degeneration - pathology ; StrN = striatonigral ; Time Factors</subject><ispartof>Brain (London, England : 1878), 2004-12, Vol.127 (12), p.2657-2671</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Dec 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-91e18e92df76b60b5fbea9ac869209ecc390e343c94763151258e3f6047a2f953</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16337167$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15509623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozawa, Tetsutaro</creatorcontrib><creatorcontrib>Paviour, Dominic</creatorcontrib><creatorcontrib>Quinn, Niall P.</creatorcontrib><creatorcontrib>Josephs, Keith A.</creatorcontrib><creatorcontrib>Sangha, Hardev</creatorcontrib><creatorcontrib>Kilford, Linda</creatorcontrib><creatorcontrib>Healy, Daniel G.</creatorcontrib><creatorcontrib>Wood, Nick W.</creatorcontrib><creatorcontrib>Lees, Andrew J.</creatorcontrib><creatorcontrib>Holton, Janice L.</creatorcontrib><creatorcontrib>Revesz, Tamas</creatorcontrib><title>The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis of 100 MSA cases with well-characterized clinical phenotypes. In 24 areas, chosen from both the striatonigral (StrN) and olivopontocerebellar (OPC) regions, the severity of neuronal cell loss and gliosis as well as the frequency of glial (oligodendroglial) cytoplasmic inclusions (GCIs) and neuronal cytoplasmic inclusions (NCIs) were determined. Clinical information was abstracted from the patients' medical records, and the severity of bradykinesia in the first year of disease onset and in the final stages of disease was graded retrospectively. The degree of levodopa responsiveness and the presence or absence of cerebellar ataxia and autonomic symptoms were also recorded. We report that 34% of the cases were SND- and 17% were OPCA-predominant, while the remainder (49%) had equivalent SND and OPCA pathology. We found a significant correlation between the frequency of GCIs and the severity of neuronal cell loss, and between these pathological changes and disease duration. Our data also suggest that GCIs may have more influence on the OPC than on the StrN pathology. Moreover, we raise the possibility that a rapid process of neuronal cell loss, which is independent of the accumulation of GCIs, occurs in the StrN region in MSA. There was no difference in the frequency of NCIs in the putamen, pontine nucleus and inferior olivary nucleus between the SND and OPCA subtypes of MSA, confirming that this pathological abnormality is not associated with a particular subtype of the disease. In the current large post-mortem series, 10% of the cases had associated Lewy body pathology, suggesting that this is not a primary process in MSA. As might be expected, there was a significant difference in the severity of bradykinesia and the presence of cerebellar signs between the pathological phenotypes: the SND phenotype demonstrates the most severe bradykinesia and the OPCA phenotype the more frequent occurrence of cerebellar signs, confirming that the clinical phenotype is dependent on the distribution of pathology within the basal ganglia and cerebellum. Putaminal involvement correlated with a poor levodopa response in MSA. Our finding that relatively mild involvement of the substantia nigra is associated clinically with manifest parkinsonism, while more advanced cerebellar pathology is required for ataxia, may explain why the parkinsonian presentation is predominant over ataxia in MSA.</description><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cell Death</subject><subject>clinicopathological correlations</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>GCI = glial cytoplasmic inclusion</subject><subject>GFAP = glial fibrillary acidic protein</subject><subject>glial cytoplasmic inclusion</subject><subject>H&amp;E = haematoxylin and eosin</subject><subject>Humans</subject><subject>IPD = idiopathic Parkinson's disease</subject><subject>Lewy Bodies - pathology</subject><subject>LFB/CV = luxol fast blue/cresyl violet</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MSA = multiple system atrophy</subject><subject>MSA-C = multiple system atrophy cerebellar type</subject><subject>MSA-P = multiple system atrophy parkinsonism</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>multiple system atrophy</subject><subject>Multiple System Atrophy - pathology</subject><subject>NCI = neuronal cytoplasmic inclusion</subject><subject>NCLPS = neuronal cell loss predominance score</subject><subject>Neurology</subject><subject>Neurons - pathology</subject><subject>Olivopontocerebellar Atrophies - pathology</subject><subject>olivopontocerebellar atrophy</subject><subject>OPC = olivopontocerebellar</subject><subject>OPCA = olivopontocerebellar atrophy</subject><subject>Phenotype</subject><subject>QSBB = Queen Square Brain Bank</subject><subject>SbN = substantia nigra</subject><subject>Severity of Illness Index</subject><subject>Sex Distribution</subject><subject>SND = striatonigral degeneration</subject><subject>striatonigral degeneration</subject><subject>Striatonigral Degeneration - pathology</subject><subject>StrN = striatonigral</subject><subject>Time Factors</subject><issn>0006-8950</issn><issn>1460-2156</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0UGL1DAYBuAgijuu3jxLEfRk3aRp0mZvOqirDAiyguwlpJmvO1nTpCbp6PwW_6ypU1z0IgQCycMbvrwIPSb4JcGCnnVBGXemvu8opnfQitQclxVh_C5aYYx52QqGT9CDGG8wJjWt-H10QhjDgld0hX5e7qCII-gUpqHwfTGqtPPWXxutbGHc3ts9DODSfJdmm4JRyTtzHTJQblt4a_Z-9C55DQE6sFaFIh5igiHmhGKYbDKjheWsUCn4cXc4L7Q1zmj_14vahwBWJeNdfIju9cpGeLTsp-jz2zeX64ty8_Hd-_WrTalrRlMpCJAWRLXtG95x3LG-AyWUbrmosACtqcBAa6pF3XBKGKlYC7TnuG5U1QtGT9HzY-4Y_LcJYpKDiXqew4GfouQNFnnx_0IiuBAtnhOf_gNv_BRcHiIbNpcg6oxeHJEOPsYAvRyDGVQ4SILlXK38Xa08Vpv5kyVz6gbY3uKlywyeLUDF_JV9UE6beOs4pQ3hTXbl0Zlcx48_9yp8zZPShsmLL1eyEa83n9ZXHySlvwBWLcFW</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>Ozawa, Tetsutaro</creator><creator>Paviour, Dominic</creator><creator>Quinn, Niall P.</creator><creator>Josephs, Keith A.</creator><creator>Sangha, Hardev</creator><creator>Kilford, Linda</creator><creator>Healy, Daniel G.</creator><creator>Wood, Nick W.</creator><creator>Lees, Andrew J.</creator><creator>Holton, Janice L.</creator><creator>Revesz, Tamas</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations</title><author>Ozawa, Tetsutaro ; Paviour, Dominic ; Quinn, Niall P. ; Josephs, Keith A. ; Sangha, Hardev ; Kilford, Linda ; Healy, Daniel G. ; Wood, Nick W. ; Lees, Andrew J. ; Holton, Janice L. ; Revesz, Tamas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-91e18e92df76b60b5fbea9ac869209ecc390e343c94763151258e3f6047a2f953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cell Death</topic><topic>clinicopathological correlations</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>GCI = glial cytoplasmic inclusion</topic><topic>GFAP = glial fibrillary acidic protein</topic><topic>glial cytoplasmic inclusion</topic><topic>H&amp;E = haematoxylin and eosin</topic><topic>Humans</topic><topic>IPD = idiopathic Parkinson's disease</topic><topic>Lewy Bodies - pathology</topic><topic>LFB/CV = luxol fast blue/cresyl violet</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MSA = multiple system atrophy</topic><topic>MSA-C = multiple system atrophy cerebellar type</topic><topic>MSA-P = multiple system atrophy parkinsonism</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>multiple system atrophy</topic><topic>Multiple System Atrophy - pathology</topic><topic>NCI = neuronal cytoplasmic inclusion</topic><topic>NCLPS = neuronal cell loss predominance score</topic><topic>Neurology</topic><topic>Neurons - pathology</topic><topic>Olivopontocerebellar Atrophies - pathology</topic><topic>olivopontocerebellar atrophy</topic><topic>OPC = olivopontocerebellar</topic><topic>OPCA = olivopontocerebellar atrophy</topic><topic>Phenotype</topic><topic>QSBB = Queen Square Brain Bank</topic><topic>SbN = substantia nigra</topic><topic>Severity of Illness Index</topic><topic>Sex Distribution</topic><topic>SND = striatonigral degeneration</topic><topic>striatonigral degeneration</topic><topic>Striatonigral Degeneration - pathology</topic><topic>StrN = striatonigral</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozawa, Tetsutaro</creatorcontrib><creatorcontrib>Paviour, Dominic</creatorcontrib><creatorcontrib>Quinn, Niall P.</creatorcontrib><creatorcontrib>Josephs, Keith A.</creatorcontrib><creatorcontrib>Sangha, Hardev</creatorcontrib><creatorcontrib>Kilford, Linda</creatorcontrib><creatorcontrib>Healy, Daniel G.</creatorcontrib><creatorcontrib>Wood, Nick W.</creatorcontrib><creatorcontrib>Lees, Andrew J.</creatorcontrib><creatorcontrib>Holton, Janice L.</creatorcontrib><creatorcontrib>Revesz, Tamas</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozawa, Tetsutaro</au><au>Paviour, Dominic</au><au>Quinn, Niall P.</au><au>Josephs, Keith A.</au><au>Sangha, Hardev</au><au>Kilford, Linda</au><au>Healy, Daniel G.</au><au>Wood, Nick W.</au><au>Lees, Andrew J.</au><au>Holton, Janice L.</au><au>Revesz, Tamas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>127</volume><issue>12</issue><spage>2657</spage><epage>2671</epage><pages>2657-2671</pages><issn>0006-8950</issn><issn>1460-2156</issn><eissn>1460-2156</eissn><coden>BRAIAK</coden><abstract>Multiple system atrophy (MSA) has varying clinical (MSA-P versus MSA-C) and pathological [striatonigral degeneration (SND) versus olivopontocerebellar atrophy (OPCA)] phenotypes. To investigate the spectrum of clinicopathological correlations, we performed a semi-quantitative pathological analysis of 100 MSA cases with well-characterized clinical phenotypes. In 24 areas, chosen from both the striatonigral (StrN) and olivopontocerebellar (OPC) regions, the severity of neuronal cell loss and gliosis as well as the frequency of glial (oligodendroglial) cytoplasmic inclusions (GCIs) and neuronal cytoplasmic inclusions (NCIs) were determined. Clinical information was abstracted from the patients' medical records, and the severity of bradykinesia in the first year of disease onset and in the final stages of disease was graded retrospectively. The degree of levodopa responsiveness and the presence or absence of cerebellar ataxia and autonomic symptoms were also recorded. We report that 34% of the cases were SND- and 17% were OPCA-predominant, while the remainder (49%) had equivalent SND and OPCA pathology. We found a significant correlation between the frequency of GCIs and the severity of neuronal cell loss, and between these pathological changes and disease duration. Our data also suggest that GCIs may have more influence on the OPC than on the StrN pathology. Moreover, we raise the possibility that a rapid process of neuronal cell loss, which is independent of the accumulation of GCIs, occurs in the StrN region in MSA. There was no difference in the frequency of NCIs in the putamen, pontine nucleus and inferior olivary nucleus between the SND and OPCA subtypes of MSA, confirming that this pathological abnormality is not associated with a particular subtype of the disease. In the current large post-mortem series, 10% of the cases had associated Lewy body pathology, suggesting that this is not a primary process in MSA. As might be expected, there was a significant difference in the severity of bradykinesia and the presence of cerebellar signs between the pathological phenotypes: the SND phenotype demonstrates the most severe bradykinesia and the OPCA phenotype the more frequent occurrence of cerebellar signs, confirming that the clinical phenotype is dependent on the distribution of pathology within the basal ganglia and cerebellum. Putaminal involvement correlated with a poor levodopa response in MSA. Our finding that relatively mild involvement of the substantia nigra is associated clinically with manifest parkinsonism, while more advanced cerebellar pathology is required for ataxia, may explain why the parkinsonian presentation is predominant over ataxia in MSA.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15509623</pmid><doi>10.1093/brain/awh303</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-8950
ispartof Brain (London, England : 1878), 2004-12, Vol.127 (12), p.2657-2671
issn 0006-8950
1460-2156
1460-2156
language eng
recordid cdi_proquest_miscellaneous_67097096
source Oxford University Press Journals; MEDLINE; EZB Electronic Journals Library
subjects Adult
Age Distribution
Aged
Aged, 80 and over
Biological and medical sciences
Cell Death
clinicopathological correlations
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
GCI = glial cytoplasmic inclusion
GFAP = glial fibrillary acidic protein
glial cytoplasmic inclusion
H&E = haematoxylin and eosin
Humans
IPD = idiopathic Parkinson's disease
Lewy Bodies - pathology
LFB/CV = luxol fast blue/cresyl violet
Male
Medical sciences
Middle Aged
MSA = multiple system atrophy
MSA-C = multiple system atrophy cerebellar type
MSA-P = multiple system atrophy parkinsonism
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
multiple system atrophy
Multiple System Atrophy - pathology
NCI = neuronal cytoplasmic inclusion
NCLPS = neuronal cell loss predominance score
Neurology
Neurons - pathology
Olivopontocerebellar Atrophies - pathology
olivopontocerebellar atrophy
OPC = olivopontocerebellar
OPCA = olivopontocerebellar atrophy
Phenotype
QSBB = Queen Square Brain Bank
SbN = substantia nigra
Severity of Illness Index
Sex Distribution
SND = striatonigral degeneration
striatonigral degeneration
Striatonigral Degeneration - pathology
StrN = striatonigral
Time Factors
title The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T16%3A49%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20spectrum%20of%20pathological%20involvement%20of%20the%20striatonigral%20and%20olivopontocerebellar%20systems%20in%20multiple%20system%20atrophy:%20clinicopathological%20correlations&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Ozawa,%20Tetsutaro&rft.date=2004-12-01&rft.volume=127&rft.issue=12&rft.spage=2657&rft.epage=2671&rft.pages=2657-2671&rft.issn=0006-8950&rft.eissn=1460-2156&rft.coden=BRAIAK&rft_id=info:doi/10.1093/brain/awh303&rft_dat=%3Cproquest_cross%3E754521171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195432694&rft_id=info:pmid/15509623&rfr_iscdi=true